Anti-HSD17B13 / Hydroxysteroid 17 beta dehydrogenase 13, clone HSD17B13/13107

1 mg/ml in 1X PBS, BSA free, sodium azide free. Hepatic lipid droplet protein antibody recognizes 17 beta hydroxysteroid dehydrogenase type 13, a liver-enriched enzyme encoded by the HSD17B13 gene that localizes predominantly to the cytoplasm and lipid droplet-associated compartments of hepatocytes. This protein belongs to the short-chain dehydrogenase reductase family and is strongly linked to hepatic lipid metabolism. Because of its restricted tissue distribution and functional association with lipid droplets, a hepatic lipid droplet protein antibody is widely used in studies of liver biology, metabolic regulation, and fatty liver disease.17 beta hydroxysteroid dehydrogenase type 13 is structurally related to other hydroxysteroid dehydrogenases but displays a distinct expression pattern that is largely confined to liver tissue. In hepatocytes, the protein associates with lipid droplets, positioning it at the interface between lipid storage and metabolic processing. Hepatic lipid droplet protein antibody-based detection enables visualization and analysis of this compartmentalized expression pattern, supporting research into lipid droplet dynamics and hepatocellular metabolism.Genetic and functional studies have identified 17 beta hydroxysteroid dehydrogenase type 13 as a key modifier of liver disease susceptibility. Loss-of-function variants in the HSD17B13 gene are associated with reduced risk of non-alcoholic fatty liver disease, steatohepatitis, and progression to advanced liver fibrosis. Conversely, altered expression of this hepatic lipid droplet protein has been reported in fatty liver disease and hepatocellular carcinoma. Use of a hepatic lipid droplet protein antibody allows researchers to examine protein-level changes associated with disease risk, progression, and tumor biology.As a member of the hydroxysteroid dehydrogenase family, 17 beta hydroxysteroid dehydrogenase type 13 contains a conserved enzymatic domain characteristic of short-chain dehydrogenase reductases. Although its precise endogenous substrates remain an area of active investigation, its lipid droplet localization suggests a role in regulating lipid-associated redox reactions or signaling pathways within hepatocytes. A hepatic lipid droplet protein antibody therefore provides a valuable tool for exploring enzyme localization, metabolic context, and functional interactions in liver cells.Expression of 17 beta hydroxysteroid dehydrogenase type 13 is minimal or absent in most extrahepatic tissues, making it a useful marker of hepatocyte identity and liver-specific metabolic states. Antibody-based detection of this hepatic lipid droplet protein is particularly useful in studies of hepatic differentiation, metabolic remodeling, and liver pathology. Clone HSD17B13/13107 is designed to recognize 17 beta hydroxysteroid dehydrogenase type 13 and supports detection of this target in relevant research applications. NSJ Bioreagents offers this hepatic lipid droplet protein antibody to support investigations into liver metabolism, fatty liver disease biology, and hepatocellular function.